Cervical Cancer Data Inject Fresh Life Into Sanofi's Libtayo
More Positive Phase III Findings For Regeneron-Partnered PD-1 Inhibitor
Libtayo is the first immunotherapy to demonstrate an improvement in OS, PFS and ORR in advanced cervical cancer and approval in this indication could kickstart its lackluster sales to date.
